NYSE:GEN - Genesis Healthcare Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.57
  • Forecasted Upside: -28.11 %
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.79
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Genesis Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GEN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.57
▼ -28.11% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Genesis Healthcare in the last 3 months. The average price target is $0.57, with a high forecast of $0.57 and a low forecast of $0.57. The average price target represents a -28.11% upside from the last price of $0.79.
Sell
The current consensus among 1 investment analysts is to sell stock in Genesis Healthcare. This rating has held steady since November 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2021Credit Suisse GroupDowngradeNeutral ➝ Underperform$0.57High
i
11/11/2020Credit Suisse GroupLower Price TargetNeutral$0.75 ➝ $0.57Medium
i
2/4/2019Credit Suisse GroupReiterated RatingHoldLow
i
11/28/2018Stifel NicolausUpgradeHold ➝ Buy$2.00 ➝ $2.50High
i
11/7/2018Cantor FitzgeraldReiterated RatingBuy$7.00High
i
10/16/2018Credit Suisse GroupInitiated CoverageNeutral$1.75Low
i
10/3/2018Cantor FitzgeraldReiterated RatingBuy$7.00Low
i
8/7/2018Cantor FitzgeraldReiterated RatingBuy$7.00High
i
4/24/2018Stifel NicolausSet Price TargetHold$2.00Medium
i
Rating by Chad Vanacore at Stifel Nicolaus
3/19/2018StephensReiterated RatingHold$2.00High
i
9/13/2017Royal Bank of CanadaReiterated RatingHold$2.00Low
i
7/5/2017Cantor FitzgeraldInitiated CoverageOverweightHigh
i
1/3/2017Royal Bank of CanadaReiterated RatingHold$3.50N/A
i
11/21/2016Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$3.00 ➝ $3.50N/A
i
9/19/2016Bank of AmericaSet Price TargetSell$1.80N/A
i
Rating by joanna gajuk at Bank of America Co.
8/22/2016UBS GroupReiterated RatingSellN/A
i
5/16/2016Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
i
5/16/2016Royal Bank of CanadaLower Price TargetOutperform$5.00 ➝ $3.00N/A
i
5/11/2016StephensDowngradeOverweight ➝ HoldN/A
i
(Data available from 2/28/2016 forward)
Genesis Healthcare logo
Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of April 23, 2020, it provided inpatient services through a network of approximately 400 skilled nursing facilities and assisted/senior living communities in 25 states; and supplied rehabilitation and respiratory therapy to approximately 1,200 healthcare locations in 44 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.
Read More

Today's Range

Now: $0.79
$0.76
$0.84

50 Day Range

MA: $0.80
$0.59
$1.14

52 Week Range

Now: $0.79
$0.40
$1.75

Volume

1,414,012 shs

Average Volume

4,588,966 shs

Market Capitalization

$132.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Genesis Healthcare?

The following Wall Street research analysts have issued reports on Genesis Healthcare in the last twelve months: Credit Suisse Group AG.
View the latest analyst ratings for GEN.

What is the current price target for Genesis Healthcare?

1 Wall Street analysts have set twelve-month price targets for Genesis Healthcare in the last year. Their average twelve-month price target is $0.57, suggesting a possible downside of 28.1%. Credit Suisse Group AG has the highest price target set, predicting GEN will reach $0.57 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $0.57 for Genesis Healthcare in the next year.
View the latest price targets for GEN.

What is the current consensus analyst rating for Genesis Healthcare?

Genesis Healthcare currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe GEN will underperform the market and that investors should sell shares of Genesis Healthcare.
View the latest ratings for GEN.

What other companies compete with Genesis Healthcare?

Other companies that are similar to Genesis Healthcare include The Ensign Group, National HealthCare, Five Star Senior Living, Diversicare Healthcare Services and Regional Health Properties.

How do I contact Genesis Healthcare's investor relations team?

Genesis Healthcare's physical mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company's listed phone number is 610-444-6350 and its investor relations email address is [email protected] The official website for Genesis Healthcare is www.genesishcc.com.